Literature DB >> 17896392

Bleomycin-induced lung injury assessed noninvasively and in spontaneously breathing rats by proton MRI.

Harry Karmouty-Quintana1, Catherine Cannet, Stefan Zurbruegg, François-Xavier Blé, John R Fozard, Clive P Page, Nicolau Beckmann.   

Abstract

PURPOSE: To apply proton magnetic resonance imaging (MRI) techniques to assess noninvasively and in spontaneously breathing rats, structural changes following a single intratracheal administration of bleomycin (BLM).
MATERIALS AND METHODS: Rats were scanned by MRI prior to BLM or vehicle administration and at six hours, 24 hours, week 1, and at weeks 2, 3, 6, and 8 after treatment. Bronchoalveolar lavage (BAL) fluid and histological analyses were performed at 24 hours, and at weeks 1 and 8 (histology only).
RESULTS: Prominent MRI fluid signals were detected in the lungs of BLM-treated rats one week after challenge. These signals correlated with increased inflammatory parameters in BAL fluid and with marked perivascular and parenchymal infiltration with inflammatory cells in histological slices. At week 2 the MRI signals due to edema resolved, but nevertheless an increase in MRI signal intensity from the lung parenchyma was apparent. In some areas of the right lung the MRI signal intensity in the parenchyma decreased between weeks 2 and 8. These observations were in line with histology demonstrating collagen deposition and atelectasis (hallmarks of fibrosis) at week 1 and a partial recovery of the lung parenchyma at week 8.
CONCLUSION: The data demonstrate the ability of proton MRI to detect BLM-induced lung fibrosis as well as the acute inflammatory response caused by the agent. (c) 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17896392     DOI: 10.1002/jmri.21100

Source DB:  PubMed          Journal:  J Magn Reson Imaging        ISSN: 1053-1807            Impact factor:   4.813


  7 in total

1.  Direct leukocyte migration across pulmonary arterioles and venules into the perivascular interstitium of murine lungs during bleomycin injury and repair.

Authors:  Ping M Wang; Diane L Kachel; Mark F Cesta; William J Martin
Journal:  Am J Pathol       Date:  2011-06       Impact factor: 4.307

2.  Magnetic resonance imaging of disease progression and resolution in a transgenic mouse model of pulmonary fibrosis.

Authors:  Zackary I Cleveland; Yu M Zhou; Teckla G Akinyi; R Scott Dunn; Cynthia R Davidson; Jinbang Guo; Jason C Woods; William D Hardie
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2017-01-27       Impact factor: 5.464

Review 3.  Noninvasive imaging of experimental lung fibrosis.

Authors:  Yong Zhou; Huaping Chen; Namasivayam Ambalavanan; Gang Liu; Veena B Antony; Qiang Ding; Hrudaya Nath; Janet F Eary; Victor J Thannickal
Journal:  Am J Respir Cell Mol Biol       Date:  2015-07       Impact factor: 6.914

4.  In vivo pharmacological evaluation of compound 48/80-induced airways oedema by MRI.

Authors:  H Karmouty-Quintana; F-X Blé; C Cannet; S Zurbruegg; J R Fozard; C P Page; N Beckmann
Journal:  Br J Pharmacol       Date:  2008-05-12       Impact factor: 8.739

5.  Noninvasive Monitoring of Bleomycin-induced Lung Injury in Rats Using Pulmonary Function Test.

Authors:  Mi-Jin Yang; Young-Su Yang; Yong-Bum Kim; Kyu-Hyuk Cho; Jeong-Doo Heo; Kyuhong Lee; Chang-Woo Song
Journal:  Toxicol Res       Date:  2008-12-01

6.  Comparison between conventional and "clinical" assessment of experimental lung fibrosis.

Authors:  Kjetil Ask; Renee Labiris; Laszlo Farkas; Antje Moeller; Aaron Froese; Troy Farncombe; Grant B McClelland; Mark Inman; Jack Gauldie; Martin R J Kolb
Journal:  J Transl Med       Date:  2008-04-10       Impact factor: 5.531

7.  Improved In vivo Assessment of Pulmonary Fibrosis in Mice using X-Ray Dark-Field Radiography.

Authors:  Andre Yaroshenko; Katharina Hellbach; Ali Önder Yildirim; Thomas M Conlon; Isis Enlil Fernandez; Martin Bech; Astrid Velroyen; Felix G Meinel; Sigrid Auweter; Maximilian Reiser; Oliver Eickelberg; Franz Pfeiffer
Journal:  Sci Rep       Date:  2015-12-01       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.